Business Wire

ChipAgents Raises Oversubscribed $21M Series A to Redefine AI for Chip Design

21.10.2025 17:30:00 EEST | Business Wire | Press release

Share

Today ChipAgents, the agentic AI platform transforming chip design and verification, announced the close of a $21 million Series A funding round, bringing the total fundraise to $24 million to date. This latest round closed with Bessemer Venture Partners, with strategic backing from Micron, MediaTek, Ericsson, and additional top semiconductor companies. Also participating in the round are notable angels including new advisors, Wally Rhines, Raúl Camposano,and Jack Harding, and existing support by ScOp Venture Capital (Ivan Bercovich) and Amino Capital, fueling the company’s expansion of product development, customer acquisition, and strategic industry partnerships.

ChipAgents’ mission is to bring the power of AI to the heart of chip design and verification. Every engineer should be empowered with tools that make the most complex aspects of hardware development faster, more intuitive, and dramatically more productive. Chips are the foundation of our digital world, yet the process of building and verifying them remains slow, costly, and labor-intensive. By rethinking workflows with AI, ChipAgents shortens design cycles, accelerates innovation, and helps semiconductor companies deliver breakthroughs that will shape the next decade of technology.

“Electronic design automation (EDA) has powered decades of semiconductor progress, but today’s engineers still struggle with fragmented toolchains, steep costs, and workflows that haven’t kept pace with rapidly growing chip complexity,” said Founder and CEO, Professor William Wang. “As designs scale, productivity gains have slowed and verification remains highly manual. Our vision is to change that. With ChipAgents, we’re introducing a unified agentic AI platform designed to automate routine tasks, accelerate design and verification, and enable AI-native workflows that help engineers focus on innovation rather than repetitive effort.”

Building on the momentum of its seed round, ChipAgents saw a 6,377% surge in monthly usage in the first half of 2025, leveraging agentic AI to accelerate RTL code generation, testbench creation, debugging, and verification through intuitive, language-based commands. The result: expedited time-to-market, cost reductions, and a redefined benchmark for productivity in chip development. Across independent teams, ChipAgents achieves 80% higher productivity in verification compared to industry practices and is deployed at 50 leading semiconductor companies, showcasing its ability to deliver real-world value at scale. The company sees a 50x YoY growth in annual recurring revenue (ARR) in the beginning of its second year.

"ChipAgents has demonstrated itself as having the best product in the market that does AI-powered RTL design, debugging, and verification for chip developers,” said Lance Co Ting Keh, Venture Partner at Bessemer Venture Partners. “We’re impressed by Professor William Wang’s deep technical expertise and the exceptional team of AI and hardware design experts he’s assembled. ChipAgents’ agentic approach to AI chip design integrates seamlessly across the entire chip design workflow, bringing together disparate EDA tools from spec ingestion to waveform analysis, which we believe is the right way to tackle this complex, multi-step process. The feedback from customers and technical experts validates that ChipAgents isn't just automating individual tasks, but creating a true force multiplier for hardware design engineers.”

“Micron Ventures supports bold AI companies led by visionary founders developing transformative technologies. ChipAgents’ mission to reinvent chip design through AI agents aligns closely with our focus, especially as chipmakers require faster, more intelligent design solutions to meet the accelerating demands of AI hardware. At this pivotal inflection point, ChipAgents presents a high-impact opportunity to invest in the future of semiconductor development,” said Henry Huang, Investment Director at Micron Ventures.

ChipAgents has also bolstered its leadership team with the formation of a world-class advisory board composed of several of the semiconductor industry’s most distinguished veterans. The new board includes Wally Rhines, former CEO of Mentor Graphics (now Siemens EDA); Raúl Camposano, former CTO of Synopsys; Jack Harding, former CEO of Cadence; and Erez Tsur, former CEO of Cadence Israel. Collectively, with additional guidance from founding advisor, Dr. John Bowers, these silicon luminaries bring decades of experience in building and scaling the very companies that have defined the EDA landscape.

"ChipAgents demonstrates the major impact that AI can have on the full range of integrated circuit design tasks,” said Wally Rhines. “I’ve met with three major semiconductor companies that have done competitive assessments of AI-based design solutions, and ChipAgents is the number one choice at all three.”

"ChipAgents is pioneering a new era in semiconductor design, where AI and engineering expertise converge for smarter solutions. The implications for the semiconductor industry are nothing short of transformative, and I’m excited to support their mission,” said Raúl Camposano.

Book a demo with ChipAgents to learn more about the agentic AI EDA platform, and check out the open positions to join the pioneering team.

About ChipAgents

ChipAgents is a cutting-edge AI startup delivering generative, agentic solutions for chip design and verification. Its flagship product transforms how hardware companies define, validate, and refine RTL code, simplifying complex workflows while driving unmatched productivity and accuracy. For more information, visit ChipAgents.ai or follow us on LinkedIn and Twitter/X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251021677325/en/

Contacts

Media Contact:
press@alphadesign.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye